Abstract
Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908-916).
| Original language | English |
|---|---|
| Pages (from-to) | 881-882 |
| Number of pages | 2 |
| Journal | Nature medicine |
| Volume | 12 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2006 |